Original Article | Published:

Transcriptional control and signal transduction, cell cycle

Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells

Leukemia volume 31, pages 14341442 (2017) | Download Citation

Abstract

Obesity is becoming more prevalent worldwide and is a major risk factor for cancer development. Acute myeloid leukemia (AML), the most common acute leukemia in adults, remains a frequently fatal disease. Here we investigated the molecular mechanisms by which obesity favors AML growth and uncovered the fatty acid-binding protein 4 (FABP4) and DNA methyltransferase 1 (DNMT1) regulatory axis that mediates aggressive AML in obesity. We showed that leukemia burden was much higher in high-fat diet-induced obese mice, which had higher levels of FABP4 and interleukin (IL)-6 in the sera. Upregulation of environmental and cellular FABP4 accelerated AML cell growth in both a cell-autonomous and cell-non-autonomous manner. Genetic disruption of FABP4 in AML cells or in mice blocked cell proliferation in vitro and induced leukemia regression in vivo. Mechanistic investigations showed that FABP4 upregulation increased IL-6 expression and signal transducer and activator of transcription factor 3 phosphorylation leading to DNMT1 overexpression and further silencing of the p15INK4B tumor-suppressor gene in AML cells. Conversely, FABP4 ablation reduced DNMT1-dependent DNA methylation and restored p15INK4B expression, thus conferring substantial protection against AML growth. Our findings reveal the FABP4/DNMT1 axis in the control of AML cell fate in obesity and suggest that interference with the FABP4/DNMT1 axis might be a new strategy to treat leukemia.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. Dnmt1 overexpression causes genomic hypermethylation, loss of imprinting, and embryonic lethality. Mol Cell Biol 2002; 22: 2124–2135.

  2. 2.

    , , , , , et al. A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis. Oncotarget 2014; 5: 5494–5509.

  3. 3.

    , , , , , et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009; 113: 6411–6418.

  4. 4.

    , , , , , et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008; 111: 2364–2373.

  5. 5.

    , , , , , et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell 2012; 22: 645–655.

  6. 6.

    , , , , , et al. AML1/ETO cooperates with HIF1alpha to promote leukemogenesis through DNMT3a transactivation. Leukemia 2015; 29: 1730–1740.

  7. 7.

    . Epigenetics advancing personalized nanomedicine in cancer therapy. Adv Drug Deliv Rev 2012; 64: 1532–1543.

  8. 8.

    , , , . Epigenetics and environment: a complex relationship. J Appl Physiol 2010; 109: 243–251.

  9. 9.

    , , . Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211–217.

  10. 10.

    , , , , , . Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796–1808.

  11. 11.

    , . Inflammation and cancer. Nature 2002; 420: 860–867.

  12. 12.

    , , . Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4: 221–233.

  13. 13.

    , , , , , et al. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res 2012; 36: 868–875.

  14. 14.

    . Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist 2010; 15: 1083–1101.

  15. 15.

    , , , , , et al. Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes. Cancer Epidemiol 2016; 40: 134–140.

  16. 16.

    , . Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008; 7: 489–503.

  17. 17.

    , . The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr 2008; 28: 73–95.

  18. 18.

    , , , , , et al. FABP 4 is associated with inflammatory markers and metabolic syndrome in morbidly obese women. Eur J Endocrinol 2011; 164: 539–547.

  19. 19.

    , , , , , . Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 2008; 118: 2640–2650.

  20. 20.

    , , , , , et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011; 17: 1498–1503.

  21. 21.

    , , , , , et al. Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma. Oncol Rep 2014; 31: 1116–1120.

  22. 22.

    , , , , . Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat 2010; 119: 367–367.

  23. 23.

    , , , , , et al. Identification of fatty acid binding protein 4 as an adipokine that regulates insulin secretion during obesity. Mol Metab 2014; 3: 465–473.

  24. 24.

    , , , , , et al. Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab 2013; 17: 768–778.

  25. 25.

    , , , , , et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52: 405–413.

  26. 26.

    , , , , , et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 2006; 12: 945–949.

  27. 27.

    , , , , , et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 2008; 112: 4193–4201.

  28. 28.

    , , , , , et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 2010; 16: 903–908.

  29. 29.

    , , , , , et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001; 97: 1172–1179.

  30. 30.

    , , , , . Quantitative multiplex quantum dot in-situ hybridisation based gene expression profiling in tissue microarrays identifies prognostic genes in acute myeloid leukaemia. Biochem Biophys Res Commun 2012; 425: 333–339.

  31. 31.

    , , , , . Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745–E751.

  32. 32.

    , , , , , et al. Obesity aggravates the joint inflammation in a collagen-induced arthritis model through deviation to Th17 differentiation. Exp Mol Med 2012; 44: 424–431.

  33. 33.

    , , , , , et al. Raised interleukin-6 levels in obese patients. Obes Res 2000; 8: 673–675.

  34. 34.

    , , , , . The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 2005; 280: 12888–12895.

  35. 35.

    , , , , , et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine 2013; 61: 885–891.

  36. 36.

    , , , , , et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103–113.

  37. 37.

    . DNA methylation, methyltransferases, and cancer. Oncogene 2001; 20: 3139–3155.

  38. 38.

    , . Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies. Int J Cancer 2008; 122: 1418–1421.

  39. 39.

    , , , , , et al. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. Am J Hematol 2013; 88: 906–909.

  40. 40.

    , , , , . Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica 2012; 97: 1401–1404.

  41. 41.

    , , , , , et al. Is obesity a prognostic factor for acute myeloid leukemia outcome? Ann Hematol 2012; 91: 359–365.

  42. 42.

    , , , , , et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 1996; 14: 3000–3008.

  43. 43.

    , , , , , et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97–101.

  44. 44.

    , . Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann NY Acad Sci 2012; 1271: 37–43.

  45. 45.

    , , , , , et al. Lipid metabolism and adipokine levels in fatty acid-binding protein null and transgenic mice. Am J Physiol Endocrinol Metab 2006; 290: E814–E823.

  46. 46.

    , , , , , et al. Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia. Genome Med 2014; 6: 34.

  47. 47.

    , , , , , . Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466: 1129–1133.

  48. 48.

    , , , , , et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839–843.

  49. 49.

    , . Cytidine deaminases: AIDing DNA demethylation? Genes Dev 2010; 24: 2107–2114.

  50. 50.

    , , , , , et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553–567.

Download references

Acknowledgements

This work was supported partially by The Hormel Foundation, National Cancer Institute (Bethesda, MD, USA) grants R01CA149623, R01CA177679, R01CA180986, R01CA104509, R21CA155915 and R03CA186176-01A1, Career Transition Fellowship (NMSS TA3047-A-1) and the Predolin Foundation. We thank Dr Jill Suttles for providing Fabp4-deficient mice, Dr Clara Nervi for providing the SKNO-1 cell line and Dr Margot P. Cleary at The Hormel Institute University of Minnesota for assistance in proofreading.

Author contributions

BL and SJL conceived ideas and designed the experiments; FY, NS, JXP, YWZ, SCW and EYR performed experiments; AA and MRL provided the leukemia patient samples; DEZ provided the AML1/ETO9a mouse model and critically reviewed the paper; FY, AMB, AA-K, MRL, BL and SJL analyzed data and wrote the paper; FY carried out the biostatistical analysis; and SJL oversaw the entire research project.

Author information

Author notes

    • B Li
    •  & S J Liu

    These authors contributed equally to this work.

Affiliations

  1. The Hormel Institute, University of Minnesota, Austin, MN, USA

    • F Yan
    • , N Shen
    • , J X Pang
    • , A M Bode
    •  & S J Liu
  2. Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA

    • Y W Zhang
    • , E Y Rao
    •  & B Li
  3. Hematology Division, Mayo Clinic, Rochester, MN, USA

    • A Al-Kali
    •  & M R Litzow
  4. Department of Pathology, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA

    • D E Zhang
  5. Division of Biological Sciences, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA

    • D E Zhang

Authors

  1. Search for F Yan in:

  2. Search for N Shen in:

  3. Search for J X Pang in:

  4. Search for Y W Zhang in:

  5. Search for E Y Rao in:

  6. Search for A M Bode in:

  7. Search for A Al-Kali in:

  8. Search for D E Zhang in:

  9. Search for M R Litzow in:

  10. Search for B Li in:

  11. Search for S J Liu in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to S J Liu.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/leu.2016.349

Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)

Further reading